| Literature DB >> 35836206 |
Tonje Teigland1,2, Jannicke Igland3,4, Grethe S Tell4, Johannes Haltbakk3, Marit Graue3, Anne-Siri Fismen3, Kåre I Birkeland5,6, Truls Østbye4,7, Mark Peyrot3,8, Marjolein M Iversen9.
Abstract
Entities:
Year: 2022 PMID: 35836206 PMCID: PMC9281115 DOI: 10.1186/s12902-022-01091-7
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 3.263
Fig. 1Study population recruited from IPLOSa and linked to data from NorPDe, showing data from 2009. a IPLOS = the Norwegian Information System for the Nursing and Care Sector, b HCS = Home care service, c DM = Diabetes mellitus, pharmacologically treated, d GLD = Glucose lowering drugs, e NorPD = Norwegian Prescription Database. Prescriptions with ATC code A10A (insulins and analogues) is defined as insulin, prescriptions with ATC code A10B (blood glucose lowering drugs, exclusive insulins) is defined as non-insulin glucose lowering drugs (non-insulin GLD) and prescriptions with either ATC code A10A or A10B is defined as glucose lowering drugs (GLD)